■ | Scientific program - 05.12.2025

Friday, December 5

from 08.00 Door opening Networking Area 08.30 – 09.45 General Assembly SGN/SSN Room Theatersaal 99.45 – 10.00 SGN Publication Award 2025 Room Theatersaal Spatiotemporal Landscape of Kidney Tubular Responses to Glomerular Proteinuria 10.00 – 10.15 Short break Networking Area 10.15 – 11.00 Parallel Symposium by Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15 – 11.00 Parallel Symposium by Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15 – 11.00 Elevator Pitch - Phase 1: all authors 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind the Titre?			
SgN Publication Award 2025 Room Theatersaal Spatiotemporal Landscape of Kidney Tubular Responses to Glomerular Proteinuria 10.00–10.15 Short break Networking Area 10.15–11.00 Parallel Symposium by Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15–11.00 Parallel Symposium by Room Ballsaal Room	from 08.00	Door opening Networking Area	Networking Area
Spatiotemporal Landscape of Kidney Tubular Responses to Glomerular Proteinuria 10.00–10.15 Short break Networking Area 10.15–11.00 Parallel Symposium by Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15–11.00 Parallel Symposium by Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15–11.00 Elevator Pitch - Phase 1: all authors Room Club Casino 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid-ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E- associated kidney disease: the discovery of HeV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind	08.30-09.45	General Assembly SGN/SSN	Room Theatersaal
Tubular Responses to Glomerular Proteinuria 10.00–10.15 Short break Networking Area 10.15–11.00 Parallel Symposium by Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15–11.00 Parallel Symposium by Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15–11.00 Elevator Pitch - Phase 1: all authors 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid-ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind	09.45-10.00	SGN Publication Award 2025	Room Theatersaal
10.15–11.00 Parallel Symposium by Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15–11.00 Parallel Symposium by Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15–11.00 Elevator Pitch - Phase 1: all authors Room Club Casino 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid-ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism undertying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind		Tubular Responses to Glomerular	Anna Faivre, Genève
Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki, Innsbruck (AUT) 10.15–11.00 Parallel Symposium by Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15–11.00 Elevator Pitch - Phase 1: all authors 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind Kerstin Hübel, Zürich	10.00-10.15	Short break	Networking Area
Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen PD Dr. med. Harald Seeger, Baden 10.15–11.00 Elevator Pitch - Phase 1: all authors Room Club Casino 10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After ABO Incompatible Kidney Transplantation: What Lurks Behind Kerstin Hübel, Zürich	10.15–11.00	Otsuka Future Perspectives of IgAN Management Prof. Dr. med. Uyen Huynh-Do, Bern PD Dr. med. Michael Rudnicki,	Room Theatersaal
10.17/EP-05 Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind	10.15–11.00	Roche Pharma (Schweiz) AG Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth, St. Gallen	Room Ballsaal
Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2 PaTH Forward Trial 10.18/EP-04 It is never too late - recovery of kidney function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind Jan Bruegger, Horgen Deborah Buess, Basel Birgit Helmchen, Zürich Kerstin Hübel, Zürich			
function with complement inhibition 10.19/EP-07 Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind Deborah Buess, Basel Birgit Helmchen, Zürich Kerstin Hübel, Zürich	10.15-11.00	Elevator Pitch - Phase 1: all authors	Room Club Casino
donation: An analysis of the Swiss Organ Living-Donor Health Registry 10.20/EP-14 Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21/EP-13 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind Birgit Helmchen, Zürich Kerstin Hübel, Zürich		Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2	
hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex glomerulonephritis 10.21 / EP-13 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind	10.17/EP-05	Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2 PaTH Forward Trial It is never too late - recovery of kidney	Olivier Bonny, Fribourg
After AB0 Incompatible Kidney Transplantation: What Lurks Behind	10.17/EP-05 10.18/EP-04	Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroid- ism: 4-Year Results From the Phase 2 PaTH Forward Trial It is never too late - recovery of kidney function with complement inhibition Metabolic risk after living kidney donation: An analysis of the Swiss	Olivier Bonny, Fribourg Jan Bruegger, Horgen
	10.17/EP-05 10.18/EP-04 10.19/EP-07	Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial It is never too late - recovery of kidney function with complement inhibition Metabolic risk after living kidney donation: An analysis of the Swiss Organ Living-Donor Health Registry Unraveling a mechanism underlying hepatitis E-associated kidney disease: the discovery of HEV ORF2 capsid protein- associated immune complex	Olivier Bonny, Fribourg Jan Bruegger, Horgen Deborah Buess, Basel

Friday, December 5

10.22/EP-06	Long-term prediction of renal function decline using diffusion MRI in kidney transplant and CKD patients	* Aurélie Huber, Genève
10.23/EP-01	"Isolated v-lesions" do not show molecular rejection, but in combination with microvascular inflammation, increase the probability of molecular mixed rejection	* Evelyn Kowarik, Luzern
10.24/ EP-11	Single-Kidney Transplantation with Discarded Partner Kidney vs. Dual Kidney Transplantation: Results from a National Cohort Study	* Christian Kuhn, St. Gallen
10.25/EP-12	sodium bicarbonate and volume retention in metabolic acidosis after kidney transplantation – a post hoc analysis	Alexander Ritter, St. Gallen
10.26/ EP-08	metabolic safety of long-term citrate therapy in high-risk kidney stone formers	Alexander Ritter, St. Gallen
10.27/ EP-10	Prognostic value of proteinuria and kidney function in patients with newly diagnosed multiple myeloma	Davide Spica, Aarau
10.28/ EP-03	Donor-derived metatastatic tumor presenting six years after kidney transplantation	Unal Tokkuzun, Lugano
10.29/ EP-02	Acute kidney injury after catheter-di- rected thrombolysis versus throm- bo-aspiration by AngioJet in patients with acute lower limb ischaemia	Antonio Ulpiano, Lausanne
10.30/ EP-09	Molecular Rejection Signals in Chronic-Active T Cell-Mediated Rejection: Histological Drivers and Potential Outcome Implications	* Lukas Weidmann, Zürich
followed by	Presentation rating by the audience	
followed by	Phase 2: selected long presentations	
11.00-11.30	Coffee break	Networking Area

^{* =} YSN submission

Friday, December 5

11.30–12.15	State of the Art Lecture 4: Phenotypic expression of kidney tubular disorders. Age matters! Prof. Dr. med. Martin Konrad, Münster (DE)	Room Theatersaal
11.30–12.15	Parallel Symposium by Novartis A new era for managing IgA nephropathy and C3G: Evolution of clinical approaches Prof. Uyen Huynh-Do, Bern Prof. Patricia Hirt-Minkowski, Basel	Room Ballsaal
11.30-12.15	SRRQAP - Swiss Dialysis Registry	Room Club Casino
12.15-13.00	Parallel Symposium by Alnylam Experiences with rare diseases in nephrology - how do you recognise and treat these patients? Prof. Dr. med. Wesley Hayes, Zürich Dr. med. Sibylle Tschumi, Bern Prof. Dr. med. Daniel Fuster, Bern	Room Theatersaal
12.15-13.00	Parallel Symposium by Swedish Orphan Biovitrum AG The Future of C3G and p IC-MPGN Treatment: Innovations and Implications for Adults and Adolescents Prof. Dr. med. Uyen Huynh-Do, Bern Prof. Dr. med. Fadi Fakhouri, Lausanne Prof. Dr. med. Wesley Hayes, Zürich	Room Ballsaal
13.00-14.00	Lunch break	Networking Area
14.00-14.45	YSN Picture Challenge	Room Theatersaal

Friday, December 5

14.00-14.45	Parallel Symposium by Spirig HealthCare AG Unlocking the Potential: IgAN-Care with Nefecon*—A New Era in Treatment. Guidelines, Evidence, and the Swiss Framework *Budesonid targeted release Dr. Oliver Phan, Lausanne Prof. Jürgen Floege, Aachen (GER) PD Dr. Harald Seeger, Baden	Room Ballsaal
	KDIGO 2025 IgA Nephropathy Guidelines: Key Updates and Clinical Implications	Jürgen Floege
	Nefecon (Kinpeygo®) in IgA Nephropathy: Evidence and the Swiss Framework	Harald Seeger
14.45-15.30	State of the Art Lecture 5: Kidney Care in an unequal World Dr. sc. med. Valerie Luyckx, Zürich	Room Theatersaal
15.30	Farewell address	Room Theatersaal

■ | Book of Abstracts

Supplement «swiss medical weekly» - December 2025

For the 57th Annual Meeting of the Swiss Society of Nephrology



This Book of Abstract was realized in cooperation with:

